The global inhaled nitric oxide market was valued at $634.4 million in 2019 and is estimated to reach $1,180.98 million by 2027, registering a CAGR of 8.1% from 2020-2027.
Nitric oxide (iNO) is selective pulmonary vasodilation and is delivered to the patient via mechanical ventilation after dilution with an oxygen/air mixture nitric oxide delivery system. Nitric oxide is a gas available in 100 ppm and 800 ppm concentrations depending on the treatment. Further, clinical trials evaluating the use of inhaled nitric oxide for numerous indications are ongoing. The potential therapeutic role of inhaled nitric oxide in adults remains uncertain at this time and FDA-approved indications are restricted to pediatric practice.
As nitric oxide exists as a gas, it can be easily administered for inhalation and is classified in the pharmacotherapeutic group. It relaxes the vascular smooth muscle by activating guanylate cyclase and increases intracellular levels of cGMP, which then leads to vasodilation and increased oxygenation. Nitric oxide is used together with a breathing machine (ventilator) and other agents to treat newborn (term and near-term) babies with respiratory failure that is caused by pulmonary hypertension.
The market growth is driven due to factors such as increase in the prevalence of diseases in the newborn such as persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF). However, a The rise in the number of patients with chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS) boost the growth of the inhaled nitric oxide market. However, the high cost of treatment and strict government regulations for various applications hamper the market growth.
Conversely, ongoing R&D activities leading to new application areas in the healthcare industry are expected to provide lucrative opportunities for the expansion of the global market in the near future.
The global inhaled nitric oxide market is segmented into application, and region. By applications, the market is divided into neonatal respiratory treatment, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and others (tuberculosis treatment). Region-wise, the market is analyzed across North America, Europe, Asia-Pacific and rest of world. Asia Pacific is expected to be a growing region shortly on account of the number of highest live birth per 1000 people and the rise in prevalence of respiratory distress syndrome, neonatal jaundice, and hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn (PPHN). The competitive market formed due to the emergence of local providers of nitric oxide therapy systems contributes toward the growth of the Asia-Pacific market.
The inhaled nitric oxide market provides extensive competitive analysis and profiles of Key market Players, such as Air Liquide S.A, Bellerophon Therapeutics, Inc., BOC Healthcare, Beyond Air, Inc, Halma Plc, Linde Plc, Novoteris, LLC, VERO Biotech LLC, and Nu-Med Plus.
Nitric oxide (iNO) is selective pulmonary vasodilation and is delivered to the patient via mechanical ventilation after dilution with an oxygen/air mixture nitric oxide delivery system. Nitric oxide is a gas available in 100 ppm and 800 ppm concentrations depending on the treatment. Further, clinical trials evaluating the use of inhaled nitric oxide for numerous indications are ongoing. The potential therapeutic role of inhaled nitric oxide in adults remains uncertain at this time and FDA-approved indications are restricted to pediatric practice.
As nitric oxide exists as a gas, it can be easily administered for inhalation and is classified in the pharmacotherapeutic group. It relaxes the vascular smooth muscle by activating guanylate cyclase and increases intracellular levels of cGMP, which then leads to vasodilation and increased oxygenation. Nitric oxide is used together with a breathing machine (ventilator) and other agents to treat newborn (term and near-term) babies with respiratory failure that is caused by pulmonary hypertension.
The market growth is driven due to factors such as increase in the prevalence of diseases in the newborn such as persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF). However, a The rise in the number of patients with chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS) boost the growth of the inhaled nitric oxide market. However, the high cost of treatment and strict government regulations for various applications hamper the market growth.
Conversely, ongoing R&D activities leading to new application areas in the healthcare industry are expected to provide lucrative opportunities for the expansion of the global market in the near future.
The global inhaled nitric oxide market is segmented into application, and region. By applications, the market is divided into neonatal respiratory treatment, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and others (tuberculosis treatment). Region-wise, the market is analyzed across North America, Europe, Asia-Pacific and rest of world. Asia Pacific is expected to be a growing region shortly on account of the number of highest live birth per 1000 people and the rise in prevalence of respiratory distress syndrome, neonatal jaundice, and hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn (PPHN). The competitive market formed due to the emergence of local providers of nitric oxide therapy systems contributes toward the growth of the Asia-Pacific market.
The inhaled nitric oxide market provides extensive competitive analysis and profiles of Key market Players, such as Air Liquide S.A, Bellerophon Therapeutics, Inc., BOC Healthcare, Beyond Air, Inc, Halma Plc, Linde Plc, Novoteris, LLC, VERO Biotech LLC, and Nu-Med Plus.
Key Benefits for Stakeholders
- This report entails a detailed quantitative analysis of the current market trends from 2019 to 2027 to identify the prevailing opportunities.
- The inhaled nitric oxide market size and estimations are based on comprehensive analysis of the key developments in the industry.
- In-depth analysis based of the region assists to understand the regional market and the strategic business planning.
- The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
Key Market Segments
By Application
- Neonatal Respiratory Treatment
- Chronic Obstructive Pulmonary Disease (COPD)
- Acute Respiratory Distress Syndrome (ARDS)
- Others (Tuberculosis Treatment)
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- Australia
- Rest of World
List of Key Players profiled in the report
- Air Liquide S.A
- Bellerophon Therapeutics, Inc.
- BOC Healthcare
- Beyond Air, Inc.
- Halma Plc
- Linde Plc
- Mallinckrodt plc
- Novoteris, LLC
- VERO Biotech LLC
- Nu-Med Plus
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: INHALED NITRic OXIDE MARKET, BY APPLICATION
CHAPTER 5: INHALED NITRic OXIDE MARKET, BY REGION
CHAPTER 6: COMPANY PROFILES
List of Tables
List of Figures
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | January 2021 |
| Forecast Period | 2019 - 2027 |
| Estimated Market Value ( USD | $ 634.4 million |
| Forecasted Market Value ( USD | $ 1180.98 million |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
